AXS-14 (esreboxetine) is a highly selective and potent norepinephrine reuptake inhibitor being developed for the management of fibromyalgia. Esreboxetine is the SS-enantiomer of racemic reboxetine.

Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced ...

Johnson & Johnson announces positive results from phase 3 MajesTEC-9 study of Tecvayli in patients with multiple myeloma: Raritan, New Jersey Friday, January 16, 2026, 10:00 Hrs [ ...

Coherus Oncology, Inc. ( CHRS) 44th Annual J.P. Morgan Healthcare Conference January 13, 2026 1:30 PM EST Good morning everyone. It's still the morning. Thanks for joining us for another session at ...

The Android 16 QPR3 Beta 2 update is now rolling out to Google's Pixel devices. It brings a ton of fixes to the table.

Google has released Android 16 QPR3 Beta 2. The latest beta includes fixes for stability, performance, and usability issues.

The first Android 16 QPR3 beta introduced features like the ability to disable the At a Glance widget on the Pixel home ...

CAPLYTA® nearly doubled the likelihood of remission at six weeks compared to placebo as an adjunctive therapy to an antidepressant based on pooled data ...

“The problem is that we do not yet have shared standards and safe, purpose-built tools as the default for classrooms,” Adeel ...

According to the latest Common App report, the number of first-year applicants to college has increased 4% compared to last year. Application volume has also grown by 7%.

Johnson & Johnson (NYSE:JNJ), a worldwide leader in multiple myeloma therapies, today announced positive topline results from the investigational Phase 3 MajesTEC-9 study of TECVAYLI® ...

A new blood marker reflects the extent of brain injury after an ischemic stroke and can predict patient outcomes months to years later.Strokes are a ...